Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Deficiency of lncRNA SNHG12 impairs ischemic limb neovascularization by altering an endothelial cell cycle pathway
David A. Gross, Henry S. Cheng, Rulin Zhuang, Michael G. McCoy, Daniel Pérez-Cremades, Zachary Salyers, A.K.M. Khyrul Wara, Stefan Haemmig, Terence E. Ryan, Mark W. Feinberg
David A. Gross, Henry S. Cheng, Rulin Zhuang, Michael G. McCoy, Daniel Pérez-Cremades, Zachary Salyers, A.K.M. Khyrul Wara, Stefan Haemmig, Terence E. Ryan, Mark W. Feinberg
View: Text | PDF
Research Article Angiogenesis Cardiology

Deficiency of lncRNA SNHG12 impairs ischemic limb neovascularization by altering an endothelial cell cycle pathway

  • Text
  • PDF
Abstract

SNHG12, a long noncoding RNA (lncRNA) dysregulated in atherosclerosis, is known to be a key regulator of vascular senescence in endothelial cells (ECs). However, its role in angiogenesis and peripheral artery disease has not been elucidated. Hind-limb ischemia studies using femoral artery ligation (FAL) in mice showed that SNHG12 expression falls readily in the acute phase of the response to limb ischemia in gastrocnemius muscle and recovers to normal when blood flow recovery is restored to ischemic muscle, indicating that it likely plays a role in the angiogenic response to ischemia. Gain- and loss-of-function studies demonstrated that SNHG12 regulated angiogenesis — SNHG12 deficiency reduced cell proliferation, migration, and endothelial sprouting, whereas overexpression promoted these angiogenic functions. We identified SNHG12 binding partners by proteomics that may contribute to its role in angiogenesis, including IGF-2 mRNA–binding protein 3 (IGF2BP3, also known as IMP3). RNA-Seq profiling of SNHG12-deficient ECs showed effects on angiogenesis pathways and identified a strong effect on cell cycle regulation, which may be modulated by IMP3. Knockdown of SNHG12 in mice undergoing FAL using injected gapmeRs) decreased angiogenesis, an effect that was more pronounced in a model of insulin-resistant db/db mice. RNA-Seq profiling of the EC and non-EC compartments in these mice revealed a likely role of SNHG12 knockdown on Wnt, Notch, and angiopoietin signaling pathways. Together, these findings indicate that SNHG12 plays an important role in the angiogenic EC response to ischemia.

Authors

David A. Gross, Henry S. Cheng, Rulin Zhuang, Michael G. McCoy, Daniel Pérez-Cremades, Zachary Salyers, A.K.M. Khyrul Wara, Stefan Haemmig, Terence E. Ryan, Mark W. Feinberg

×

Figure 4

Pull-downs of SNHG12-interacting proteins.

Options: View larger image (or click on image) Download as PowerPoint
Pull-downs of SNHG12-interacting proteins.
SNHG12 not only interacts wit...
SNHG12 not only interacts with DNAPK but also interacts with several other proteins as shown in vitro and in vivo. The expression of these is decreased in gastrocnemius muscle in CLI in a human cohort. (A) Proteomics was performed and yielded protein hits from both biotin-labeled LacZ and SNHG12 (n = 2 biological replicates and n = 2 technical replicates each). Common proteins were overlaid for each group, and those unique to SNHG12 demonstrated several unique nonribosomal proteins as shown in the protein score plot. (B) RNA immunoprecipitation pull-down of biotinylated in vitro–transcribed LacZ or SNHG12 RNA with HUVEC lysate shows specific enrichment of DNAPK, IGF2 mRNA–binding protein 3 (IGF2BP3, also known as IMP3), RNA helicase A (DHX9), and YBX1 (n = 3). (C) LncRNA pull-down of SNHG12 by immunoprecipitation of IMP3, YBX1, DHX9, and DNAPK from HUVEC nuclear lysate shows enrichment of SNHG12 compared with negative control (IgG) (n = 3). (D) Mice injected with in vitro–transcribed 2′-O-methylated, biotinylated LacZ or Snhg12 underwent aortic harvesting, tissue disruption, nuclear isolation, and subsequent immunoprecipitation using magnetic streptavidin beads, showing enrichment of DNAPK, DHX9, IMP3, and YBX1 (from aortae pooled from 4 mice in each group). (E) Expression levels of IMP3, YBX1, DHX9, and DNAPKcs are all decreased in CLI patients versus ischemic claudicants (IC) or healthy adults (HA) from a cohort of patients aged 51–84 who underwent gastrocnemius biopsy and whole transcriptome sequencing (n = 15 for HA, n = 20 for IC, and n = 16 for CLI). *P < 0.05, ****P < 0.01 using Student’s t test or 1-way ANOVA with Bonferroni correction.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts